



ifw

PATENT
Attorney Docket No.: UBC1180-2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Hancock et al.	Art Unit:	1614
Application No.:	10/661,471	Examiner:	Not Yet Assigned
Filed:	September 12, 2003	Conf. No.:	7167
Title:	EFFECTORS OF INNATE IMMUNITY DETERMINATION		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL SHEET

Sir:

Transmitted herewith for the above-identified application, please find:

- (1) Information Disclosure Statement (2 pgs.);
- (2) PTO Form 1449 (2 pgs.);
- (3) Eight (8) References;
- (4) International Search Report (9 pgs.); and
- (5) Return postcard.

CERTIFICATION UNDER 37 CFR §1.8

I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on **March 16, 2005**, in an envelope addressed to: Mail Stop: Amendments, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Lisa E. Jambeau

Lisa E. Jambeau


In re Application of:
Hancock et al.
Application No.: 10/661,471
Filed: September 12, 2003
Page 2

PATENT
Attorney Docket No.: UBC1180-2

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement as the items of information contained in this statement were cited in a communication from a foreign patent office in a counterpart foreign application, the communication being dated December 16, 2004, which is not more than three months prior to the filing of this statement. However, if any fee is required, authorization is hereby given to charge the amount of any such fee, or credit any overpayment, to Deposit Account No. 07-1896.

Respectfully submitted,

Date: March 16, 2005



Lisa A. Haile, J.D. Ph.D.
Registration No. 38,347
Telephone: (858) 677-1456
Facsimile: (858) 677-1465

DLA PIPER RUDNICK GRAY CARY US LLP
4365 Executive Drive, Suite 1100
San Diego, California 92121-2133
USPTO Customer No. 28213



PATENT
Attorney Docket No.: UBC1180-2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Hancock et al.	Art Unit:	1614
Application No.:	10/661,471	Examiner:	Not Yet Assigned
Filed:	September 12, 2003	Conf. No.:	7167
Title:	EFFECTORS OF INNATE IMMUNITY DETERMINATION		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT


Sir:

In accordance with 37 C.F.R. § 1.97, enclosed are references relating to the above-identified application. Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. For the convenience of the Examiner, these references are listed on the attached Form PTO-1449 and copies are enclosed herewith.

It is respectfully requested that these references be considered in the examination of this application and their consideration be made of written record in the application file.

CERTIFICATION UNDER 37 CFR §1.8

I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on **March 16, 2005**, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Lisa E. Jambeau


In re Application of:
Hancock et al.
Application No.: 10/661,471
Filed: September 12, 2003
Page 2

PATENT
Attorney Docket No.: UBC1180-2

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement as the items of information contained in this statement were cited in a communication from a foreign patent office in a counterpart foreign application, the communication being dated December 16, 2004, which is not more than three months prior to the filing of this statement. However, if any fee is required, authorization is hereby given to charge the amount of any such fee, or credit any overpayment, to Deposit Account No. 07-1896.

Respectfully submitted,

Date: March 16, 2005




Lisa A. Haile, J.D., Ph.D.
Registration No.: 38,347
Telephone: (858) 677-1456
Facsimile: (858) 677-1465

BEST AVAILABLE COPY

DLA PIPER RUDNICK GRAY CARY US LLP
4365 Executive Drive, Suite 1100
San Diego, California 92121-2133
USPTO Customer Number 28213

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Docket No. UBC1180-2	Serial No.: 10/661,471
	Applicant: Hancock et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date: September 12, 2003	Group Art Unit: 1614



U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION (YES/NO)
	AA	CA2456477A1	02/27/03	Canada			No
	AB	CA2468907A1	06/12/03	Canada			No

BEST AVAILABLE COPY

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

	AC	Scott MG. et al., "The Human Antimicrobial Peptide LL-37 Is a Multifunctional Modulator of Innate Immune Responses", <i>The Journal of Immunology</i> , Vol. 169, 3883-3891, 2002
	AD	Hancock R.E. et al., "The role of cationic antimicrobial peptides in innate host defenses", <i>Trends in Microbiology</i> , Vol. 8, No. 9, 402-410, September 2000
	AE	Hancock, R.E., "Host Defense (Cationic) Peptides, What is Their Future Clinical Potential?", <i>Drugs</i> , Vol. 57, No. 4, 469-473, April 1999
	AF	Finlay, B.B. et al., "Perspectives, Can innate immunity be enhanced to treat microbial infections?", <i>Nature Reviews Microbiology</i> , Vol. 2, 497-504, June 2004
	AG	Giacometti et al., "Potential Therapeutic Role of Cationic Peptides in Three Experimental Models of Septic Shock", <i>Antimicrobial Agent and Chemotherapy</i> , 2132-2136, July 2002

EXAMINER GT\6438738.1 104776-27	DATE CONSIDERED
---	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Department of Commerce Patent and
Trademark Office

Docket No.

UBC1180-2

Serial No.:

10/661,471

Applicant: Hancock et al.

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

Filing Date:

September 12, 2003

Group Art Unit:

1614

AH

Bowdish, D.M.E., et al., "The Human Cationic Peptide LL-37 Induces Activation of the Extracellular Signal-Regulated Kinases and p38 Kinase Pathways in Primary Human Monocytes", *The Journal of Immunology*, Vol. 172, 3758-3765, 2004

BEST AVAILABLE COPY

EXAMINER

GT6438738.1
104776-27

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.